Steven Cohen’s Point72 Asset Management disclosed a 5.2% stake in Design Therapeutics (DSGN), which represents over 2.94M shares. The filing with the SEC does not allow for activism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
- Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial Caution
- Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
- Design Therapeutics reports Q2 EPS (34c), consensus (33c)
- Design Therapeutics Faces Financial Strain Amid International Trade Challenges